Reprogramming Human Cells With bit.bio's Mark Kotter, M.D.

We love to hear from our listeners. Send us a message.

The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial.  Bit.bio is exemplary of this new breed. Its CEO, Dr. Mark Kotter doesn’t pull any punches when addressing the complexity involved in building out the company’s capabilities. At the discovery stage alone, bit.bio has hired – and integrated – stem cell biologists, synthetic biologists, genetic engineering experts, cellular biologists, sequencing experts, data scientists, bioinformatics pros, and machine learning experts. 
On this episode of the Business of Biotech, recorded in San Francisco during JPM Week, we catch up with Dr. Kotter on the work bit.bio is doing, how it’s doing it, and how he and his leadership team are recruiting and retaining a new breed of biotech talent to sustain the effort. Let’s give it a listen. 

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/